Sign In

AHA Guidance on Incidentally Identified CVD Gene Variants

Core Concepts
Guidance on handling incidental CVD gene variants.
The American Heart Association (AHA) has issued guidance on managing genetic tests that unexpectedly reveal gene variants linked to inherited cardiovascular disease (CVD). The statement outlines steps to assess variant risks, communicate with patients, and recommend follow-up care for high-risk variants. The guidance focuses on monogenic CVD genes and emphasizes the importance of interpreting and translating genetic findings into clinical practice. Recommendations include relaying information to patients, obtaining family history, and periodic reevaluation of genetic variants to ensure accurate risk assessment and appropriate medical interventions.
The American College of Medical Genetics and Genomics identifies 42 clinically treatable secondary variant genes increasing the risk of sudden cardiac death, heart failure, and other CVD.
"It's also important to consult with genetics specialists to custom-tailor an evaluation and treatment plan to both the individual and the genetic variant in order to ensure the highest level of care possible." - Andrew P. Landstrom

Key Insights Distilled From

by Megan Brooks at 03-28-2023
AHA Issues Advice on Incidentally Identified CVD Gene Variants

Deeper Inquiries

How can genetic testing advancements impact the future of cardiovascular disease management?

Genetic testing advancements can revolutionize cardiovascular disease management by enabling personalized medicine approaches. By identifying specific gene variants associated with inherited CVD, healthcare providers can tailor treatment plans to individual patients based on their genetic predispositions. This targeted approach can lead to more effective interventions, early detection of potential risks, and improved outcomes for patients. Additionally, genetic testing can help in identifying at-risk individuals before symptoms manifest, allowing for proactive measures to prevent or mitigate the progression of cardiovascular diseases.

What are potential drawbacks or limitations of relying on genetic testing for CVD risk assessment?

While genetic testing for CVD risk assessment offers valuable insights, there are several drawbacks and limitations to consider. One limitation is the complexity of interpreting genetic variants, especially when variants have uncertain associations with cardiovascular diseases. False positives or false negatives can occur, leading to unnecessary anxiety or missed opportunities for intervention. Additionally, genetic testing may not account for environmental factors or lifestyle choices that also influence CVD risk. There is also the risk of genetic discrimination, where individuals may face challenges in obtaining insurance or employment based on their genetic information. Furthermore, genetic testing can be costly, limiting access for some individuals.

How can interdisciplinary collaboration enhance the care provided to individuals with incidental CVD gene variants?

Interdisciplinary collaboration plays a crucial role in optimizing care for individuals with incidental CVD gene variants. By involving specialists from various fields such as genetics, cardiology, primary care, and genetic counseling, a comprehensive and personalized care plan can be developed. Genetic specialists can provide expertise in interpreting genetic variants, while cardiologists can offer insights into the cardiovascular implications of these variants. Primary care providers can coordinate overall patient care and ensure that genetic information is integrated into the management plan. Genetic counselors can help patients and families understand the implications of genetic test results and make informed decisions. This collaborative approach ensures that individuals with incidental CVD gene variants receive holistic care that addresses both their genetic predispositions and overall health needs.